Report

EyeGate Pharmaceuticals - Positive signals in OBG PRK and PE studies

EyeGate reported data in its Ocular Bandage Gel (OBG) studies in punctate epitheliopathies (PE) and in corneal wound healing following bilateral photorefractive keratectomy (PRK) surgery. The PRK study showed improved wound healing and the PE trial showed improvement in patient symptoms. EyeGate will meet with the FDA to discuss whether the existing data are sufficient for a 510(k) de novo regulatory filing.
Underlying
EYEGATE PHARMACEUTICALS INC

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Pooya Hemami

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch